A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.

Also called NCT07116863

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 286 participants (enrolled count) (from the registry)
Sponsor
Kyungdong Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT07116863
Other papers using this trial's data
  • Efficacy and Safety Profile of a Triple Single-Pill Combination of Valsartan/Amlodipine/Chlorthalidone in Patients with Uncontrolled Hypertension Clinical therapeutics, 2026-10 DOI, PubMed 42259717

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07116863. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-21 (actual); primary completion 2024-06-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
KDF1901-R0
Intervention (Drug)
KDF1901-L
Intervention (Drug)
KDF1901
Intervention (Drug)
KDF1901-R1
Lead sponsor
Kyungdong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07116863
Content hash
f7f6b3684623c8540cbbd9031a1df660396eaa92fcf4dc921ba4dad1e19a379e